|
|
In several clinical trials Gelclair® showed good results in term of:
- reduction of pain and improvement of ability to eat and drink
- reduction of the severity of mucositis
- impact on quality of life (QoL) and acceptability of the product by patients
Of particular relevance is the study by Flook et al., in which Gelclair® was shown to be better tolerated and at least as effective as benzydamine, a topical FANS widely used for mucositis therapy and recommended by the MASCC/ISOO guidelines for patients undergoing RT.
|
|
|
|
|
|
|
|
|
D'Andrea et al.
The D'Andrea study, performed on 53 patients receiving therapy for cancer, showed that Gelclair® is an effective intervention in terms of improvements in pain, functionality, and grade of mucositis.
|
|
Read more
|
|
|
Lindsay G et al.
The Linsay et al. study demonstrated a significant efficacy of Gelclair® in reducing pain scores in 33 head and neck cancer patients with oral mucositis receiving radiotherapy.
|
|
Read more
|
|
|
De Cordi D et al.
The study demonstrated the efficacy of Gelclair® in patients undergoing different chemotherapy treatments.
|
|
Read more
|
|
|
Flook C et al.
Gelclair® was shown to be at least as effective as benzydamine (recommended for the treatment of oral mucositis caused by radiotherapy by MASCC guidelines) in managing pain caused by oral mucositis.
|
|
Read more
|
|
|